CombiMatrix Corp

CombiMatrix — IPO Roadshow (February 2016)

31 slides from CombiMatrix's IPO roadshow presentation, Feb 22, 2016

  1. Slide 1: Forward-looking statements

    This presentation, the accompanying prospectus, and the information incorporated by reference herein or therein, contain forward-looking statements, within the meaning of the ‘‘safe harbor’’ provisions of the Private Securities Litigation Reform Act of 1995, regarding us which include, but are not l

  2. Slide 2: Offering and market data notice

    This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in our company. Except as otherwise indicated, this present

  3. Slide 3: Transaction Overview

    Issuer: CombiMatrix Corporation Exchange: NASDAQ:CBMX Offering Size: $8.4 million Use of Proceeds: R&D Working Capital Sales & Marketing Repurchase of Series E Convertible Preferred Stock Bookrunners: Ladenburg Thalmann & Co. Inc. (Sole Bookrunning Manager) Aegis Capital Corp. (Lead Manager) Transac

  4. Slide 4: Investment Highlights

    Investment Highlights Executing on Commercial Plan Direct sales channel - specialists in the markets Consistent expansion of customer base Increase in reach & frequency of calls through partners Leverage same physician call points for multiple tests – to drive more revenue per doctor Proven reimburs

  5. Slide 5: Company Overview and Case Study

    Company Overview and Case Study Experienced Management Team Recent Highlights of Business Execution Growth of Reproductive Health Microarray Business

  6. Slide 6: Company Overview

    CombiMatrix offers DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methods. Specialize in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric development disorders. 2015 Sales: $10.088 Million. 21 T

  7. Slide 7: Case Study: Prenatal screening

    Case Study: 41 year old female presented for prenatal care at 11 weeks of gestation Nuchal thickness is within normal range Risk of a chromosomal abnormality based on maternal age is 1 in 53 Patient choose non-invasive prenatal screening (NIPS) over invasive testing (CVS, Amniocentesis) Results indi

  8. Slide 8: Microarray Testing vs. Karyotyping

    The American Congress of Obstetricians and Gynecologists recommends:(1) Microarray as first-tier test for stillbirths and diagnostic procedures All positive NIPS reflexed to invasive procedure High false positivity rate with NIPS(2) Array is best diagnostic test for invasive procedures(3) 5% positiv

  9. Slide 9: Miscarriage case study

    Miscarriage at 10 weeks of gestation 31 year-old G2P0 presents at ER with vaginal bleeding ER sends tissue to pathology; path tech puts tissue in formalin Karyotype not possible microarray! OB notified, requests karyotype Cannot perform karyotype on formalin-fixed tissue Pathologist suggests microar

  10. Slide 10: High-Tech, High-Touch Business Model

    High-Tech, High-Touch Business Model Sample Overnighted to CombiMatrix Sample Analyzed & Report Generated Medical Team Support for Abnormal Results Physician Makes Treatment Decisions Based on Test Results Initial Physician Consultation Testing Ordered & Sample Collected

  11. Slide 11: Experienced Management Team

    Network Commerce, Inc. Scott Burell – CFO, Secretary and Treasurer Kim Leroux – VP, Reimbursement and Billing Trilohchan Sahoo, M.D., F.A.C.M.G. – VP, Clinical Affairs Mark McDonough – CEO & President Karine Hovanes, Ph.D. – VP, Scientific Advancement Karen Warner, RN, BSN – VP, Payer Relations Expe

  12. Slide 12: Highlights of Business Execution – last 12 Months

    Delivered new products to market (three new products) Increased the number of covered lives (40%) Contributed to changes in Medical policy that support our tests through Payer interaction Drove scientific advancement through platform presentations at national meetings and publications in peer review

  13. Slide 13: Microarray Business Outpacing Overall Revenue

    Microarray Business Outpacing Overall Revenue 25% YOY revenue growth Microarray Business YOY growth of 33% 26.3% Growth 25.4% Growth 42.8% Growth 33.1% Growth CBMX Revenue in Millions USD (2013 – 2015) CBMX Reproductive Health Microarray Revenue in Millions USD (2013 – 2015) $6.367 $8.042 $10.088 $5

  14. Slide 14: Growing Reproductive Health Microarray Business

    Volume Revenue ($MM) Growing Reproductive Health Microarray Business 138% increase 197% increase Microarray Business growing - key business opportunity for CBMX. $0.8 $1.9 $0.5 $0.9 $1.3 $1.7 $2.1 Q1'13 Q4'15 461 1,369 0 300 600 900 1,200 1,500 Q1'13 Q4'15

  15. Slide 15: Prenatal and Genetic Testing Market

    Prenatal and Genetic Testing Market Pre-Implantation Genetic Screening Miscarriage Analysis Testing Prenatal Diagnostic Testing Postnatal Diagnostic Testing

  16. Slide 16: Prenatal and Newborn Genetic Testing Market

    Prenatal and Newborn Genetic Testing Market ($Bn)(1) Prenatal and Newborn Genetic Testing Market The global market for prenatal and newborn genetic testing is estimated to be valued at $8.4 billion by 2019 (a +600% increase vs. 2012 of $1.1 billion).(1) The Northwestern Medical Faculty foundation st

  17. Slide 17: U.S. Market Opportunity – Reproductive Health

    U.S. Market Opportunity – Reproductive Health CBMX estimates the total diagnostic market to be valued at ~$575 million(1) per year. Miscarriage / IUFD Analysis $300M(1) Pre-Implant Testing $75M(1) Postnatal $100M(1) Prenatal $100M(1) U.S. Market Opportunity ($M) Size of the market are CBMX estimates

  18. Slide 18: Pre-Implantation Genetic Screening Market

    Rate of Pregnancy with PGS We believe the pre-implantation genetic screening (PGS) market is experiencing growth as the procedure can help increase the effectiveness of IVF (in-vitro fertilization) treatments. Pre-Implantation Genetic Screening - $75M Market(1) Harton GL, Munné S, Surrey M, Grifo J,

  19. Slide 19: Miscarriage / IUFD Analysis Testing

    Customers Medical Benefits MFMs OB/GYNs Pathologists Reproductive Endocrinologists Provides high-resolution diagnosis of genetic disorders that account for 50% of miscarriages before 20 weeks gestation Avoids costly evaluations if chromosomal etiology uncovered, saving >$3,000 per patient* Allows in

  20. Slide 20: Prenatal Diagnostic Testing

    Prenatal Diagnostic Testing - $100M Market(1) Customers Medical Benefits Maternal Fetal Medicine specialists (MFMs) OB/GYNs Genetic Counselors Provides high-resolution diagnosis of cytogenetic disorders Allows parents to make informed decisions Widespread support for microarray technology from publi

  21. Slide 21: Postnatal Diagnostic Testing

    Postnatal Diagnostic Testing - $100M Market(1) Customers Medical Benefits Pediatric Neurologists Clinical Geneticists Behavioral Pediatricians Children’s Hospitals American College of Medical Genetics(1), American Academy of Pediatrics(2), American Academy of Neurology(3) recommend testing for one o

  22. Slide 22: Sales Channel and Territories; Reimbursement Strategy

    Sales Channel and Territories Reimbursement Strategy

  23. Slide 23: CombiMatrix Sales Channel & Territories

    AK HI WA OR NV ID MT WY UT AZ NM CO TX KS OK NE SD MN IA MO AR LA IL WI MI TN OH MS AL ME GA SC NC VT NH CT MA RI DE MD DC KY WV IN VA ND NV PA NJ FL CA NY Core Market Sales (Miscarriage Analysis, Prenatal, IVF, and Postnatal) 11 metro area territory managers and one National Account Manager Fertili

  24. Slide 24: Reimbursement Strategy

    Expertise and Talent Lale White, Board member - CEO of Xifin (Billing Software) Kim Leroux, VP of Billing - President Elect of CCLA Karen Warner, VP of Payer Relations - invited Speaker and Panelist at multiple diagnostic reimbursement conferences Strategy Thought leader involvement Persistence and

  25. Slide 25: CBMX Cash to Revenue Ratio

    CBMX Cash to Revenue Ratio CBMX has achieved reimbursements of over 93% on submitted claims to insurers. CBMX continues to show data showing that microarray test is clinically viable and medically necessary Presented data in January 2016 on over 8,000 miscarriage cases highlighting the efficacy of t

  26. Slide 26: Financial Summary, Cap Table, 2016 Strategy

    Financial Summary Cap / Ownership Table 2016 Strategy and Upcoming Milestones

  27. Slide 27: Financial Summary

    Summary Income Statement and Cash Flows (in thousands) Q4-2014 Q4-2015 FY 2014 FY 2015 Total Revenue $2,217 $2,684 $8,042 $10,088 YOY Growth 26.5% 21.1% 26.3% 25.4% Reproductive Health Microarray Revenue $1,416 $1,878 $5,071 $6,748 YOY Growth 37.2% 32.6% 42.8% 33.1% Cash Used in Operations ($2,061)

  28. Slide 28: Cap / Ownership Table

    Cap / Ownership Table OWNERSHIP TABLE as of February 12, 2016 Holder Name # of Beneficial Shares % Total Officers & Directors 28,678 3.3% Ownership >5% Edward Hamilton 115,230 13.5% Alpha Capital 85,025 9.9% Acuta Capital Partners 56,885 6.7% Perkins Capital Management 69,100 8.1% Public Float(1) 49

  29. Slide 29: 2016 Strategy / Upcoming Milestones

    CBMX is focused on the following initiatives for the coming year Continue on growth trajectory Launch new assays in the Fertility testing space to augment our offering Realize increased efficiencies in the laboratory Publish studies and data supporting the clinical validity and utility of our testin

  30. Slide 30: CombiMatrix Corporation contact

    CombiMatrix Corporation (NASDAQ:CBMX) 310 Goddard Suite 150 Irvine, CA 92618 Mark McDonough Chief Executive Officer & President 949.255.1580 mmcdonough@combimatrix.com

  31. Slide 31: CombiMatrix

    CombiMatrix CombiMatrix Corporation (NASDAQ:CBMX) 310 Goddard Suite 150 Irvine, CA 92618 Mark McDonough Chief Executive Officer & President 949.255.1580 mmcdonough@combimatrix.com

CombiMatrix — IPO Roadshow (February 2016) on 6ix